It can be seen from analysis on major blood grouping analyzer-related patent applications published in the 3 years from 2018 to 2021 that benefited from the basically stable original technologies of the industry; domestic enterprises have continuously increased R&D inputs, constantly improved technical innovation capability, made breakthroughs in many technologies, and developed a batch of core components of instruments with independent intellectual property rights through follow-on R&D strategy.

China plans to accelerate the establishment of a tiered healthcare delivery system, focusing on strengthening primary-level medical capacity to manage common and chronic diseases such as hypertension and diabetes, authorities said.

Grail has raised $300 million in a Series C financing round that wasoversubscribed, according to the firm.Ally Bridge Group led the round alongwith Hillhouse Capital Group and 6 Dimensions Capital. Blue Pool Capital, ChinaMerchant Securitie

Freenome has initiated a clinical study tohelp bring an AI-Genomics blood test for colorectal cancer to the U.S. market. Freenome is looking to build a diagnostictest that can learn from its mistakes. The South San Francisco, CA- basedcompa